Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Celldex Therapeutics, Inc. CLDX
$33.70
+$0.64 (1.91%)
На 18:00, 12 мая 2023
+86.94%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1567601687.00000000
-
week52high
48.40
-
week52low
19.85
-
Revenue
2357000
-
P/E TTM
-13
-
Beta
2.10795800
-
EPS
-2.36000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 10:59
Описание компании
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| SVB Leerink | Outperform | Outperform | 09 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 01 июл 2022 г. |
| Jefferies | Buy | 17 сент 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 13 сент 2021 г. |
| SVB Leerink | Outperform | 10 сент 2021 г. | |
| Guggenheim | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KELER TIBOR | D | 43140 | 16860 | 07 дек 2022 г. |
| KELER TIBOR | D | 7357 | 16860 | 07 дек 2022 г. |
| KELER TIBOR | A | 24217 | 16860 | 07 дек 2022 г. |
| Cavanaugh Sarah | D | 10103 | 1355 | 18 авг 2022 г. |
| Cavanaugh Sarah | D | 10750 | 31312 | 18 авг 2022 г. |
| Cavanaugh Sarah | D | 1284 | 1355 | 18 авг 2022 г. |
| Cavanaugh Sarah | A | 2639 | 1355 | 18 авг 2022 г. |
| Young Diane C. | D | 15000 | 45000 | 17 авг 2022 г. |
| Young Diane C. | D | 48400 | 19000 | 17 авг 2022 г. |
| Young Diane C. | A | 47115 | 45000 | 17 авг 2022 г. |
Новостная лента
Celldex Therapeutics (CLDX) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:44
Celldex Therapeutics (CLDX) came out with a quarterly loss of $0.62 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $0.49 per share a year ago.
Strength Seen in Celldex (CLDX): Can Its 7.1% Jump Turn into More Strength?
Zacks Investment Research
18 апр 2023 г. в 07:38
Celldex (CLDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
GlobeNewsWire
29 мар 2023 г. в 09:01
HAMPTON, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in a fireside chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference on Thursday, March 30th at 11:30 am ET. A webcast of the presentation will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay will be available for 90 days following the event.
Celldex: Long List Of Failures, High Valuation, But Good Data Recently
Seeking Alpha
20 февр 2023 г. в 05:10
Celldex has failed too many times to inspire confidence. The company's current valuation is also quite high.
Celldex to Participate in Upcoming November Investor Conferences
GlobeNewsWire
10 ноя 2022 г. в 16:01
HAMPTON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that management will participate in fireside chats at the following investor conferences in November: